Cumberland Pharmaceuticals (CPIX) Lowered to “Hold” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research lowered shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) from a strong-buy rating to a hold rating in a research note published on Tuesday, Zacks.com reports.

According to Zacks, “Cumberland Pharmaceuticals, Inc., headquartered in Nashville, Tennessee, is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets. The company’s lead product candidate, Amelior, which is in phase III clinical trials, is an intravenous formulation of ibuprofen for the treatment of both pain and fever. Its products also comprise Acetadote, an intravenous formulation of N-acetylcysteine for the treatment of acetaminophen poisoning; and Kristalose, a prescription laxative product, which is a crystalline form of lactulose to enhance patient acceptance and compliance. In addition, the company is developing a treatment for fluid buildup in the lungs of cancer patients and an anti-infective for treating fungal infections in immuno-compromised patients. “

Separately, TheStreet upgraded Cumberland Pharmaceuticals from a d+ rating to a c- rating in a report on Wednesday, April 10th.

NASDAQ:CPIX opened at $6.40 on Tuesday. Cumberland Pharmaceuticals has a fifty-two week low of $4.83 and a fifty-two week high of $7.00. The company has a current ratio of 2.07, a quick ratio of 1.67 and a debt-to-equity ratio of 0.36. The stock has a market cap of $99.44 million, a PE ratio of -53.33 and a beta of 0.28.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings data on Tuesday, May 14th. The specialty pharmaceutical company reported $0.09 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.22. Cumberland Pharmaceuticals had a positive return on equity of 2.54% and a negative net margin of 10.57%. The business had revenue of $11.90 million for the quarter, compared to analysts’ expectations of $10.70 million. As a group, equities analysts expect that Cumberland Pharmaceuticals will post -0.22 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Stonepine Capital Management LLC lifted its stake in Cumberland Pharmaceuticals by 7.8% in the 4th quarter. Stonepine Capital Management LLC now owns 1,313,429 shares of the specialty pharmaceutical company’s stock valued at $7,920,000 after acquiring an additional 95,028 shares in the last quarter. BlueCrest Capital Management Ltd bought a new stake in Cumberland Pharmaceuticals in the 1st quarter valued at approximately $63,000. Finally, Renaissance Technologies LLC lifted its stake in Cumberland Pharmaceuticals by 2.5% in the 1st quarter. Renaissance Technologies LLC now owns 390,777 shares of the specialty pharmaceutical company’s stock valued at $2,270,000 after acquiring an additional 9,403 shares in the last quarter. Hedge funds and other institutional investors own 31.35% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.

See Also: How Do Tariffs Affect Trade Balances?

Get a free copy of the Zacks research report on Cumberland Pharmaceuticals (CPIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Shavon Cape Purchases 3,790 Shares of Eagle Bancorp Montana Inc  Stock
Shavon Cape Purchases 3,790 Shares of Eagle Bancorp Montana Inc Stock
Dean Foods Co  CEO Purchases $81,000.00 in Stock
Dean Foods Co CEO Purchases $81,000.00 in Stock
Cardiovascular Systems Inc  General Counsel Alexander Rosenstein Sells 1,136 Shares
Cardiovascular Systems Inc General Counsel Alexander Rosenstein Sells 1,136 Shares
Cardiovascular Systems Inc  Insider Sells $41,506.92 in Stock
Cardiovascular Systems Inc Insider Sells $41,506.92 in Stock
First Seacoast Bancorp  Director Erica A. Johnson Buys 2,796 Shares
First Seacoast Bancorp Director Erica A. Johnson Buys 2,796 Shares
Jillian B. Thomsen Sells 1,809 Shares of Nektar Therapeutics  Stock
Jillian B. Thomsen Sells 1,809 Shares of Nektar Therapeutics Stock


 
© 2006-2019 Zolmax.